Low Risk of Renal Dysfuntion in Patients With Wilms Tumor Undergoing Partial Nephrectomy
the ONA take:
Patients with unilateral Wilms tumor who underwent unilateral radical nephrectomy without nephrotoxic chemotherapy or ionizing radiotherapy appear to have a low risk for developing significant long-term renal dysfunction, according to a study published last month in the journal Cancer.
Wilms tumor is a malignant tumor of the kidney and is the most common type of kidney cancer in children. The American Cancer Society estimates that there are about 500 new cases of Wilms tumor diagnosed in the United States each year.
For the study, researchers sought to evaluate the impact of partial nephrectomy on long-term renal dysfunction in children with unilateral Wilms tumor who were not treated with nephrotoxic chemotherapy or ionizing radiation.
Results showed that during the 19.6 years of median follow-up, 21.3% of the 75 patients had an estimated glomerular filtration rate (eGFR) <90 mL/minute/1.73m2 and 12.5% had proteinuria. Researchers found that no patients had an eGFR <60 mL/minute/1.73m2 and 6.7% of patients had hypertension.
Patients with unilateral Wilms tumor who underwent unilateral radical nephrectomy appear to have low risk for renal dysfunction.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Depression Predictive of Poor Survival Outcomes in Head and Neck Cancer
- Nearly One Third of Veterans Report Current Tobacco Use
- Priority Review of New Drug Application Granted to Apalutamide for CRPC
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|